MET and neoplasm: Activation of c-MET and VEGFR2 in OS correlates positively with tumor necrosis following cisplatin plus doxorubicin treatment, suggesting their potential as predictive biomarkers and supporting c-MET-based individualized combination strategies. (Type B)